Who
Gregory S. Moss
Director
Company insider
Files Form 4 as: Director, Anteris Technologies Global; Chief Business & Legal Officer, Evommune; EVP, Gen. Coun. / CCO., Kadmon Holdings.
In numbers
- Trades disclosed
- 29
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $649K
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 30 Aug 2019
- Last trade
- 7 Jun 2026
- Last filed
- 9 Jun 2026
Companies traded
Activity over time
1 May – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Jun 2026filed 9 Jun 2026 | AVR Anteris Technologies GlobalMedical Devices | SEC FORM 4 Code M | —17,580 | filing |
| 7 Jun 2026filed 9 Jun 2026 | AVR Anteris Technologies Globaloption or derivative · Medical Devices | SEC FORM 4 Code M | —17,580 at $0.00 | filing |
| 7 Jun 2026filed 9 Jun 2026 | AVR Anteris Technologies Globaloption or derivative · Medical Devices | SEC FORM 4 Code M | —17,580 at $0.00 | filing |
| 7 Jun 2026filed 9 Jun 2026 | AVR Anteris Technologies GlobalMedical Devices | SEC FORM 4 Code M | —17,580 | filing |
| 28 May 2026filed 1 Jun 2026 | EVMN EvommuneBiotechnology | SEC FORM 4 Code M | $24K14,223 at $1.71 | filing |
| 28 May 2026filed 1 Jun 2026 | EVMN EvommuneBiotechnology | SEC FORM 4 Sold | $325K14,223 at $22.83 | filing |
| 28 May 2026filed 1 Jun 2026 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code M | —14,223 at $0.00 | filing |
| 28 May 2026filed 1 Jun 2026 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code M | —14,223 at $0.00 | filing |
| 28 May 2026filed 1 Jun 2026 | EVMN EvommuneBiotechnology | SEC FORM 4 Code M | $24K14,223 at $1.71 | filing |
| 28 May 2026filed 1 Jun 2026 | EVMN EvommuneBiotechnology | SEC FORM 4 Sold | $325K14,223 at $22.83 | filing |
| 16 Apr 2026filed 17 Apr 2026 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —115,279 at $0.00 | filing |
| 16 Apr 2026filed 17 Apr 2026 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —115,279 at $0.00 | filing |
| 9 Dec 2025filed 11 Dec 2025 | EVMN EvommuneBiotechnology | SEC FORM 4 Code F | $243K13,624 at $17.84 | filing |
| 3 Dec 2025filed 5 Dec 2025 | AVR Anteris Technologies Globaloption or derivative · Medical Devices | SEC FORM 4 Code A | —52,742 at $0.00 | filing |
| 3 Dec 2025filed 5 Dec 2025 | AVR Anteris Technologies Globaloption or derivative · Medical Devices | SEC FORM 4 Code A | —13,821 at $0.00 | filing |
| 7 Nov 2025filed 12 Nov 2025 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code C | —25,000 | filing |
| 7 Nov 2025filed 12 Nov 2025 | EVMN EvommuneBiotechnology | SEC FORM 4 Code C | —3,175 | filing |
| 5 Nov 2025filed 7 Nov 2025 | EVMN Evommuneoption or derivative · Biotechnology | SEC FORM 4 Code A | —293,496 at $0.00 | filing |
| 9 Nov 2021filed 9 Nov 2021 | Kadmon Holdingsoption or derivative | SEC FORM 4 Code D | $363K75,000 at $4.84 | filing |
| 9 Nov 2021filed 9 Nov 2021 | Kadmon Holdingsoption or derivative | SEC FORM 4 Code D | $879K150,000 at $5.86 | filing |
News
Evommune (NYSE:EVMN) Stock Bumped Up to "Hold" by UBS GroupEVMN · tickerreport.com · 14 Oct 2026Evommune (NYSE:EVMN) Upgraded at UBS GroupEVMN · dailypolitical.com · 14 Oct 2026
0 headlines in the last 90 days name Gregory S. Moss; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.